SPRAVATO™ Depression Treatment
If you struggle with treatment-resistant depression, there's somewhere to turn.
If you've struggled with depression and tried two or more antidepressants of adequate dose and duration during your current episode without adequate relief, talk to your doctor to see if you may have TDR and if SPRAVATO™ should be a part of your overall treatment plan.
Why is SPRAVATO different?
SPRAVATO™ nasal spray is a different kind of medication for treatment-resistant depression. Today's most commonly used oral antidepressants are thought to treat depression by increasing levels of neurotransmitters (serotonin, norepinephrine, and dopamine) in areas of the brain that affect mood.
SPRAVATO™ targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently that currently available oral antidepressants.
The results speak for themselves.
In a short-term clinical study of adults with treatment-resistant depression, those who used SPRAVATO and an oral antidepressant experienced improvement (of at least 50%) of depression symptoms at four weeks compared to people who recieved a placebo and an oral antidepressant.
In a long-term study after 16 weeks of therapy, those patients who stayed on SPRAVATO did better than those who stopped therapy.